Harsco (HSC) Stock

- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites -   - New trial to expand ongoing clinical research of motixafortide for mobilization of HSCs in patients with SCD - TEL AVIV, Israel , May 30, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center Phase 1 clinical trial sponsored  by St. Jude Children's Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).

Here is how Crawford (CRD.A) and Harsco (HSC) have performed compared to their sector so far this year.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harsco (HSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

The mean of analysts' price targets for Harsco (HSC) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

HSC's revenue growth should continue to benefit from higher price realization and healthy demand across both its businesses. Margins should benefit from pricing actions and productivity improvements.

Harsco Corporation (NYSE:HSC ) Q1 2023 Earnings Conference Call May 3, 2023 10:00 AM ET Company Participants David Martin - VP of IR Nick Grasberger - Chairman and CEO Pete Minan - SVP and CFO Conference Call Participants Larry Solow - CJS Securities Rob Brown - Lake Street Capital Markets Brian Butler - Stifel Operator Good morning. My name is Sarah, and I will be your conference facilitator.